On December 11, 2024, lawmakers presented a bipartisan initiative to direct pharmaceutical middlemen to divest from health insurance companies and pharmaceutical companies, stressing concerns over vertical integration. In parallel action, the Federal Trade Commission (FTC) has commenced reviewing monopolistic practices in the industry. This action comes as part of general…
This article is available to Insider Pro subscribers only.Sign in or register to be an Insider Pro and access ALL LOCKED articles.
Fed official warns of market correction
AM Best Downgrades Credit Ratings for Members of Columbia Lloyds Companies
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News